Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor ...

SGR-1505 is under clinical development by Schrodinger and currently in Phase I for Primary Mediastinal B-Cell Lymphoma.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.

Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone deacetylase (HDAC) inhibitor, which was approved by the FDA in November 2009 to treat cutaneous T cell lymphoma (CTCL ...

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic alternatives. The company, a subsidiary of Citius Pharmaceuticals, is ...

SNGX said it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma ... The primary efficacy assessment occurred ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR ) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR ), today announced significant progress in ...